semaglutide normal bmi Comparison of body weight parameters for versus placebo In recent years, injectable weight-loss

In a 72-week study, participants receiving the maximum dose of tirzepatide lost an average of 21% of their body weight, while the placebo group experienced a 3% loss

European Journal of Pharmacology, 873, 172974

A lack of one or more of these leads to a whole range of issues caused by health problems, such as fatigue, anemia, mood disorders, and damage to nerves

We're here to discuss the implications and the path forward

Although neither of these trials specifically targeted CHE nor demonstrated a significant reduction in OHE, many of the enrolled patients were likely to have CHE, and the results of the LiveSMART trial suggest potential clinical benefits of CHE-directed therapy beyond OHE prevention